Penn Alzheimer's Disease Research Center (ADRC)

宾夕法尼亚州立大学ADRC总体项目摘要 宾夕法尼亚大学阿尔茨海默病研究中心(Penn ADRC)的使命是 加强对阿尔茨海默病(AD)及其与相关痴呆(ADRD)的联系的研究和教育 确定AD/ADRD的原因和治疗方法的目标。为了做到这一点，宾夕法尼亚大学ADRC将解决 有效治疗或预防的根本障碍，这是重要的表型、病理和 阿尔茨海默病的社会人口异质性。我们将欣然接受并努力描述和理解这一点 异质性最终实现精准医学方法，从而产生有针对性的干预措施， 促进实现《国家阿尔茨海默氏症项目法》的雄心勃勃的有效预防或 到2025年进行治疗。事实上，宾夕法尼亚大学亚洲发展研究中心的建立是为了直接促进一些里程碑。 国家适应行动方案是实现这一目标所必需的。 从宾夕法尼亚阿尔茨海默病核心中心(ADCC)30年的历史中脱颖而出的宾夕法尼亚ADRC 受益于一个丰富的科学环境，在这个环境中，宾夕法尼亚大学的 神经退行性疾病中心。这一结构对于理解AD异质性至关重要 这在一定程度上是由重叠的病理和机制驱动的，以至于交叉退行性疾病 研究在捕捉疾病的全部谱系方面变得越来越重要。这种环境导致了 影响对疾病定义和机制的理解的变革性研究的历史， 诊断方法和生物标记物开发，统计和生物信息学方法，以及伦理， 对患有这种疾病的人及其护理伙伴的社会和法律观点。它还创造了 智力、文化和物质环境致力于培训下一代调查人员和 临床医生，以及合作伙伴和教育社区。 为了实现我们的使命，宾夕法尼亚大学ADRC将汇集八个核心(行政；生物标记物；临床； 数据管理和统计；基因组学；神经成像；神经病理学；外展、招募和 参与)和研究教育部分(REC)。这些高度集成的内核将支持 一个表型、病理和种族多样性的队列的发展将深入 以认知评估、健康、遗传、生物流体和社会决定因素的测量为特征 神经成像生物标记物和尸检。所有这些数据都将存储在集成的神经退行性疾病 疾病数据库(INDD)，该数据库与宾夕法尼亚大学的其他神经退行性疾病中心相联系，将有助于 有助于我们理解导致AD异质性及其下游的上游因素和过程 表现形式。此外，ADRC支持积极分享这些数据，并参与更大规模的NIA和 国家计划。REC利用这些核心及其研究计划来培训新的调查人员。 同心协力，宾夕法尼亚大学ADRC将推进我们的最终使命，减轻AD的巨大负担。

Penn ADRC Overall Project Summary The mission of the University of Pennsylvania’s Alzheimer’s Disease Research Center (Penn ADRC) is to increase research and education on Alzheimer’s disease (AD) and its links to related dementias (ADRD) with the goal of identifying the causes of and cures for AD/ADRD. To do so, the Penn ADRC will address one of the fundamental barriers to effective treatment or prevention, which is the significant phenotypic, pathological, and sociodemographic heterogeneity of AD. We will embrace and seek to characterize and understand this heterogeneity to ultimately achieve a precision medicine approach leading to targeted interventions that will facilitate realization of the National Alzheimer’s Project Act’s (NAPA) ambitious goal of effective prevention or treatment by 2025. Indeed, the Penn ADRC is constructed to directly contribute to a number of the milestones of NAPA necessary to achieve this goal. Emerging from the 30-year history of the Penn Alzheimer’s Disease Core Center (ADCC), the Penn ADRC benefits from a rich scientific milieu in which there is significant integration and collaboration across Penn’s neurodegenerative disease centers. This construction is critical to the understanding of AD heterogeneity which is driven, in part, by overlapping pathologies and mechanisms, such that cross-degenerative disease studies are of increasing importance in capturing the full spectrum of disease. This environment has led to a history of transformative research that has influenced understanding of disease definition and mechanisms, diagnostic approaches and biomarker development, statistical and bioinformatics methodology, and ethical, social and legal perspectives of those suffering from this condition and their care partners. It has also created an intellectual, cultural, and physical setting dedicated to training the next generation of investigators and clinicians, as well as partnering and educating the community. To achieve our mission, the Penn ADRC will bring together eight cores (Administrative; Biomarker; Clinical; Data Management and Statistical; Genomics; Neuroimaging; Neuropathology; Outreach, Recruitment, and Engagement) and the Research Education Component (REC). These highly integrated cores will support development of a phenotypically, pathologically, and ethno-racially diverse cohort which will be deeply characterized through cognitive assessments, measures of social determinants of health, genetics, biofluid and neuroimaging biomarkers, and autopsy. All these data will be stored within the Integrated Neurodegenerative Disease Database (INDD), which is linked to the other neurodegenerative centers at Penn and will contribute to our understanding of the upstream factors and processes that lead to AD heterogeneity and its downstream manifestations. Further, the ADRC supports robust sharing of these data and participation in larger NIA and national programs. The REC leverages these cores and their research programs for training new investigators. Together, the Penn ADRC will advance our ultimate mission to reduce the tremendous burden of AD.